Alphatec Holdings, Inc. (NASDAQ:ATEC) General Counsel Sells $269,751.72 in Stock

Key Points

• Tyson Eliot Marshall, General Counsel of Alphatec Holdings, sold 18,092 shares for approximately $269,752, reducing his stake by 3.96% but still retains over 438,000 shares valued at around $6.54 million.
• Alphatec's stock increased by 3.2%, reaching a price of $15.34, with a trading volume significantly higher than average at nearly 5.88 million shares.
• The company's quarterly earnings report showed an EPS of $0.02, exceeding expectations, and a 27.5% revenue increase year-over-year, with analysts predicting a consensus target price of $18.50 for the stock.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) General Counsel Tyson Eliot Marshall sold 18,092 shares of Alphatec stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $14.91, for a total value of $269,751.72. Following the completion of the transaction, the general counsel owned 438,331 shares of the company's stock, valued at approximately $6,535,515.21. The trade was a 3.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Tyson Eliot Marshall also recently made the following trade(s):

• On Friday, August 1st, Tyson Eliot Marshall sold 12,878 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total transaction of $154,536.00.
• On Thursday, July 10th, Tyson Eliot Marshall sold 1,500 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total value of $18,000.00.

Alphatec Stock Up 0.5%

Shares of NASDAQ ATEC traded up $0.07 during trading hours on Friday, hitting $14.97. The company had a trading volume of 1,745,343 shares, compared to its average volume of 2,816,030. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $15.46. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The firm's 50 day moving average is $11.63 and its 200-day moving average is $11.28. The stock has a market capitalization of $2.22 billion, a P/E ratio of -13.25 and a beta of 1.05.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.08. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The firm had revenue of $185.54 million during the quarter, compared to the consensus estimate of $178.85 million. During the same period last year, the business posted ($0.29) earnings per share. The business's revenue for the quarter was up 27.5% compared to the same quarter last year. On average, analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Piper Sandler reissued an "overweight" rating and issued a $15.00 price target (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. Barclays reaffirmed an "overweight" rating and set a $22.00 price objective (up previously from $21.00) on shares of Alphatec in a research report on Monday, August 4th. Needham & Company LLC reiterated a "buy" rating and set a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Finally, Wall Street Zen raised shares of Alphatec from a "hold" rating to a "buy" rating in a report on Saturday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $18.50.

Institutional Trading of Alphatec

Several institutional investors and hedge funds have recently modified their holdings of ATEC. Raymond James Financial Inc. acquired a new position in Alphatec in the 4th quarter valued at approximately $358,000. Commonwealth Equity Services LLC increased its holdings in Alphatec by 55.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 36,929 shares of the medical technology company's stock valued at $339,000 after purchasing an additional 13,246 shares during the period. KLP Kapitalforvaltning AS bought a new position in Alphatec during the 4th quarter worth $228,000. LPL Financial LLC lifted its holdings in Alphatec by 19.9% during the 4th quarter. LPL Financial LLC now owns 413,235 shares of the medical technology company's stock worth $3,793,000 after buying an additional 68,516 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Alphatec by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,968,980 shares of the medical technology company's stock valued at $54,795,000 after buying an additional 47,797 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.